AstraZeneca AZN, +0.48% AZN, +0.40% is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma MREO, +16.03%, The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist’s partners, which include Novartis NVS, +0.60%, OncXerna and Ultragenyx RARE, -1.36%.
This article was originally published by Marketwatch.com. Read the original article here.
